Navigation Links
Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
Date:9/21/2009

SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it will re-focus its resources on the approval of OPAXIO(TM) for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the use of 12 months of OPAXIO therapy versus an untreated control arm. To date, 600 patients have been enrolled in this trial. CTI has discussed with the GOG, several strategies for conducting an interim analysis which could potentially result in an earlier registration. In addition, given the encouraging results of treatment of advanced esophageal cancer with OPAXIO to be reported at the upcoming International Society of Gastrointestinal Oncology Annual Meeting, CTI plans on meeting with the Food and Drug Administration (FDA) to discuss an additional registration study utilizing OPAXIO as a radiation sensitizer in the treatment of advanced esophageal cancer.

CTI has notified the European Medicines Agency (EMEA) of its decision to withdraw its Marketing Authorization Application (MAA) for a non-inferiority indication in non-small cell lung cancer (NSCLC).

"Given that we have reached a milestone in the ovarian cancer trial enrollment coupled with the reservations the Committee for Medicinal Products for Human Use (CHMP) expressed about the control arm activity in the NSCL cancer study we believe it makes best sense for CTI to focus its efforts with OPAXIO on superiority applications like the first-line ovarian cancer trial as well as the exciting new potential application as a radiation sensitizer," noted Craig W. Philips, President of CTI. "Both of these studies would be landmark trials and first in class for this novel bioengineered taxane. We look forward to continuing to work with the GOG and ultimately the FDA on a registr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... AVAX Technologies, Inc. (Pink Sheets: AVXT) ... recently closed a bridge loan financing (the "2009 ... Purchase Agreement (the "Agreement") with Firebird Global Master ... Company sold a convertible promissory note, due June ... US$1,400,000, and issued a warrant to purchase an ...
(Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
(Date:12/16/2009)... -- Greenway Medical Technologies, Inc. today announced that ... practice management and interoperability solution, Prime Suite® ... the annual 2009 Top 20 Best in ... report. ,, For practices having between six and ... Best in KLAS in ambulatory EMR for the ...
Breaking Medicine Technology:AVAX Technologies, Inc. Closes Bridge Financing 2AVAX Technologies, Inc. Closes Bridge Financing 3AVAX Technologies, Inc. Closes Bridge Financing 4RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Zogenix and Astellas Enter Exclusive Co Promotion Agreement in the US for Newly Approved Sumavel 28TM 29 DosePro 28TM 29 53474 1Zogenix and Astellas Enter Exclusive Co Promotion Agreement in the US for Newly Approved Sumavel 28TM 29 DosePro 28TM 29 53474 2Zogenix and Astellas Enter Exclusive Co Promotion Agreement in the US for Newly Approved Sumavel 28TM 29 DosePro 28TM 29 53474 3Zogenix and Astellas Enter Exclusive Co Promotion Agreement in the US for Newly Approved Sumavel 28TM 29 DosePro 28TM 29 53474 4NovaBay 28R 29 Pharmaceuticals Names Roy J Wu as Senior Vice President for Business Development 13326 1NovaBay 28R 29 Pharmaceuticals Names Roy J Wu as Senior Vice President for Business Development 13326 2NovaBay 28R 29 Pharmaceuticals Names Roy J Wu as Senior Vice President for Business Development 13326 3Blood Type May Boost Pancreatic Cancer Risk 53472 1Blood Type May Boost Pancreatic Cancer Risk 53472 2
(Date:12/16/2009)... from Episencial Offers Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging ... ... Los Angeles, CA (PRWEB) December 16, 2009 -- ... affordable choice in all natural skin care for their children ... for young children featuring the beloved artwork of The Very ...
(Date:12/16/2009)... caution, though, that no direct link has been found, ... bacteria in food -- commonly linked to food poisoning ... might also be the cause of some urinary tract ... the bacteria in chicken from stores and restaurants and ... evidence that the germs were transmitted directly to the ...
(Date:12/16/2009)... and MassBio promote Massachusetts companies through annual marketing campaign ... ... 2009 -- BioSpace unveiled the 2010 Genetown™ Hotbed Campaign ... , , , ,Genetown is sponsored by MassBio ... device industries. The campaign places each entity’s brand on an ...
(Date:12/16/2009)... Deaths also at all-time low, government report shows, , , ... in the United States has reached almost 78 years, ... From birth in 2007, women can expect to live ... years, according to the report from the U.S. Centers ... though Americans can expect to live longer than their ...
(Date:12/16/2009)... travel facilitator Companion Global Healthcare Inc. has accepted ... network of international hospitals that treat American patients ... U.S. facilities. ,, The announcement means Companion Global ... pricing for its individual clients and employer group ... Pablo Bayamon or HIMA San Pablo Caguas. ,, ...
Breaking Medicine News(10 mins):Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3Health News:Thriving Bioscience Region Leaves Its Mark 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2
... Just last spring,SafeSmart, Inc. launched SafetyTies, antimicrobial ... and food-borne illness. Already, the medical,marketplace is ... illness,prevention, thanks to its participation in the ... St. Louis, October 2007. Headquartered in ...
... object, but these noises may boost fitness , , WEDNESDAY, Oct. 24 ... is honest about it: When exercising, she sometimes grunts. , "I ... during a workout, and I think that most people do," said ... it,s a release." , But not everyone is so accepting ...
... AIGISRx DEB is designed to reduce the severity of capsular ... ... capsule formation, MONMOUTH ... the commercialization of implantable medical-pharmaceutical,devices, announced today acceptance for presentation ...
... shortage ... facing the industry, SOUTH BEND, Ind., ... and recognition for work done,as the top areas hospitals need to ... on American Health Care.,The report was released today by Press Ganey ...
... 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: CMED ), a ... and high intensity focused ultrasound tumor,therapy systems, today announced the following investor events: ... ... Location UBS ...
... Can be Achieved ... Without Fear of Side Effects, LONDON, October 24 ... new study published in the,International Journal of Impotence Research reveals (1). ... performance, these,categories, do not reveal the qualities, benefits or even disappointments,for ...
Other Medicine News:Health News:SafeSmart, Inc. Presents SafetyTies to Sixth Annual MedAssets Technology Forum 2Health News:Experts Sound Off on Workout Grunting 2Health News:Experts Sound Off on Workout Grunting 3Health News:TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD 2Health News:TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD 3Health News:Nurses and Hospital Employees' Top Concerns: Communication, Staffing and Compensation 2Health News:China Medical Technologies to Participate in Investor Events in November 2Health News:Now Every Man Can Enhance His Performance, Whatever His Sexual Style 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: